Table 4. Performance of sCD26, FIT and their combination for the detection of advanced adenomas.
| sCD26 (⩽330 ng ml−1)a | sCD26 (⩽280 ng ml−1)b | FIT (⩾100 ng ml−1) | sCD26 (⩽330 ng ml−1)a and/or FIT (⩾100 ng ml−1) | sCD26 (⩽280 ng ml−1)b and/or FIT (⩾100 ng ml−1) | |
|---|---|---|---|---|---|
|
All locations (n=53) | |||||
| Specificity % (95% CI) | 90.2 (87.1–92.8) | 95.2 (92.8–97.0) | 98.0 (96.3–99.1) | 88.5 (85.2–91.2) | 93.5 (90.8–95.5) |
| Sensitivity % (95% CI) | 39.6 (26.5–54.0) | 28.3 (16.8–42.3) | 32.1 (19.9–46.3) | 62.3 (47.9–75.2) | 52.8 (38.6–66.7) |
|
P-valuec |
0.572 |
0.839 |
— |
<0.001 |
0.001 |
|
Distal (n=39) | |||||
| No. of cases detected |
15/39 (38.5%) |
11/39 (28.2%) |
16/39 (41.0%) |
26/39 (66.7%) |
23/39 (59.0%) |
|
Proximal (n=14) | |||||
| No. of cases detected | 6/14 (42.9%) | 4/14 (28.6%) | 1/14 (7.1%) | 7/14 (50.0%) | 5/14 (35.7%) |
Abbreviations: CI=confidence interval; FIT=faecal immunochemical test; sCD26=soluble CD26.
The sCD26 cutoffs were selected setting specificity close to
a
90.0%.
b
95.0%.
c
P-value for McNemar test comparing the proportion of advanced adenomas detected (sensitivity) with sCD26 or its combination with FIT in relation to only FIT.